Biologos, an ISO 13485-certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions for life sciences companies, announced the appointment of Hetal Patel as chief executive officer as the company marks its 50th anniversary and accelerates investments aimed at expanding its capabilities.
Founded in 1976, Biologos has built its reputation supplying sterile-filtered buffers, media, reagents, and sera to customers across the biopharma, cell and gene therapy, tissue processing, and animal health sectors. The company originally focused on the animal health market before expanding into tissue processing in 2012 and entering biopharma and cell and gene therapy markets in 2021.
The leadership appointment comes as the company advances its next phase of growth following its acquisition by Ampersand Capital Partners in 2024. The private equity firm has supported investments in facilities and operational capabilities designed to strengthen Biologos’ position in high-growth life sciences markets.
Patel joined Biologos in 2024 as chief operating officer and has more than 25 years of experience driving commercial growth, operational performance, and organizational transformation across regulated life sciences environments. Since joining the company, she has helped prepare the business to support customers operating in increasingly complex manufacturing and development environments.
Biologos operates from a purpose-built, 32,000-square-foot ISO 13485-certified and GMP-compliant facility in Glendale Heights, Illinois. The site was designed to expand production capacity and incorporates built-in redundancies to ensure reliable, uninterrupted manufacturing for customers.
The company said the expanded facility and its fulfillment infrastructure support customers’ just-in-time inventory management requirements while maintaining rigorous quality standards. Biologos currently maintains a 98% customer retention rate and aims to deepen relationships with existing partners while expanding into fast-growing biopharma and advanced therapy markets.
As the company continues to scale, Biologos said it remains focused on delivering high-quality, GMP-compliant liquid solutions that integrate into customers’ manufacturing workflows and help accelerate product development timelines.
KEY QUOTES
“Biologos has an exceptional legacy built on integrity, agility, and an unwavering commitment to customers. With Ampersand’s support and the investments we’ve made in our people, facilities, and capabilities, we are uniquely positioned to help customers accelerate development timelines, ensure supply continuity, and confidently scale from early research through GMP manufacturing.”
Hetal Patel, Chief Executive Officer, Biologos
“For five decades, Biologos has earned the trust of its customers through consistent performance and exceptional service. With Hetal’s leadership and the company’s expanded capabilities, Biologos is well positioned to deepen existing customer relationships and continue expanding into high-growth biopharma and CGT markets.”
Eric Lev, General Partner, Ampersand Capital Partners
